

Active substances set

Search phrase: ixazomib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Multiple myeloma and plasma cell neoplasms

Ixazomib

Ixazomib in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.



NO REIMBURSEMENT



ESMO